Trial Profile
Phase II study with temozolomide and capecitabine for patients with refractory colorectal cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Oct 2016
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Temozolomide (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- Acronyms TEM
- 18 Oct 2016 New trial record
- 11 Oct 2016 Results (n=40) presented at the 41st European Society for Medical Oncology Congress.